Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Cash & Equivalents (2016 - 2025)

STRATA Skin Sciences' Cash & Equivalents history spans 14 years, with the latest figure at $7.1 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents changed 0.2% year-over-year to $7.1 million; the TTM value through Sep 2025 reached $7.1 million, changed 0.2%, while the annual FY2024 figure was $7.3 million, 7.03% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $7.1 million at STRATA Skin Sciences, up from $6.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $13.0 million in Q3 2021 and bottomed at $2.8 million in Q1 2023.
  • The 5-year median for Cash & Equivalents is $7.1 million (2023), against an average of $7.9 million.
  • The largest annual shift saw Cash & Equivalents crashed 74.14% in 2023 before it skyrocketed 85.38% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $12.6 million in 2021, then tumbled by 56.83% to $5.4 million in 2022, then increased by 24.84% to $6.8 million in 2023, then increased by 7.03% to $7.3 million in 2024, then fell by 2.55% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for SSKN's Cash & Equivalents are $7.1 million (Q3 2025), $6.0 million (Q2 2025), and $6.5 million (Q1 2025).